Clinical Trials Logo

Pancreatic Cancer clinical trials

View clinical trials related to Pancreatic Cancer.

Filter by:

NCT ID: NCT06282809 Not yet recruiting - Pancreatic Cancer Clinical Trials

The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy

GANNON
Start date: June 2024
Phase: N/A
Study type: Interventional

The purpose of this trial is to evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using histotripsy.

NCT ID: NCT06278493 Completed - Pancreatic Cancer Clinical Trials

A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer

Start date: August 23, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a clinical study to observe the tolerance and primary efficacy of AL2846 capsules combined with Gemzar injection in patients with pancreatic cancer, and to determine the recommended dosage and administration method for subsequent clinical studies.

NCT ID: NCT06276803 Not yet recruiting - Pancreatic Cancer Clinical Trials

The LINFU® U.S. Registry for the in the General Population Without Risk Factors

Start date: April 15, 2024
Phase:
Study type: Observational [Patient Registry]

Adenocyte has developed LINFU®, (Low Intensity Non-Focused Ultrasound excitation of the pancreas) as a method of identifying early, asymptomatic pancreatic cancer and its noninvasive precancerous lesions.. In this study, LINFU® will be evaluated in the general population with no risk factors and who exhibit no signs or symptoms of disease, This study will help determine if LINFU® can be used to help identify early, asymptomatic pancreatic ductal adenocarcinoma (PDAC) or their precursor lesions (PanIn-2, PanIn-3).

NCT ID: NCT06276738 Not yet recruiting - Pancreatic Cancer Clinical Trials

The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of Disease

Start date: March 30, 2024
Phase:
Study type: Observational [Patient Registry]

Evaluate LINFU® in patients who exhibit signs or symptoms (i.e. jaundice, abdominal pain, weight loss, nausea and vomiting etc.) suggestive of pancreatic cancer (PDAC) or have evidence of imaging studies suggestive of PDAC.

NCT ID: NCT06270082 Recruiting - Colorectal Cancer Clinical Trials

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Start date: December 18, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit.

NCT ID: NCT06268106 Not yet recruiting - Anxiety Clinical Trials

Graphic Novel for Patients Undergoing EUS-FNB

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

Endoscopy with endoscopic ultrasound (EUS) is a primary technique for diagnosing and treating severe pancreatic disorders. However, the procedure can cause fear and anxiety in patients, especially when a biopsy is involved. Graphic medicine, a form of visual storytelling that explores narratives of healthcare, is being used to alleviate this anxiety. This is a prospective single-center interventional pilot study with the aim to evaluate the impact of a novel graphic on the stress and behaviors of patients with pancreatic lesions undergoing EUS-FNB. The study will run for six months with the aim to enroll patients to llok for differences in the anxiety and stress levels. Enrolled patients will be randomly allocated to the test or control group, with the test group receiving a graphic novel to read while waiting for the procedure. Post-procedure, patients will complete the Beck Anxiety Inventory (BAI) and a modified version of the Depression Anxiety Stress Scales-21 (mDASS-21), now named mASS-14 (modified Anxiety Stress Scales-14), to assess anxiety and stress levels. This study is conducted according to the principles of the Declaration of Helsinki regarding experimentation involving human subjects, and written informed consent will be obtained from all participants before enrollment.

NCT ID: NCT06267690 Completed - Pancreatic Cancer Clinical Trials

A CT-based Radiomics Model to Predict Survival-graded Fibrosis in PDAC

Start date: January 13, 2021
Phase:
Study type: Observational

Tumor fibrosis plays an important role in chemotherapy resistance in pancreatic ductal adenocarcinoma (PDAC), however there remains a contradiction in the prognostic value of fibrosis. We aimed to investigate the relationship between tumor fibrosis and survival in patients with PDAC, classify patients into high- and low-fibrosis groups, and develop and validate a CT-based radiomics model to non-invasively predict fibrosis before treatment.

NCT ID: NCT06259058 Not yet recruiting - Pancreatic Cancer Clinical Trials

Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer

Start date: April 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This multicentric open-label trial will compare the efficacy and safety of stereotactic body radiation therapy (SBRT) followed by NALIRIFOX (5-fluorouracil, leucovorin, irinotecan liposome injection and oxaliplatin) vs NALIRIFOX for borderline resectable pancreatic cancer (BRPC).

NCT ID: NCT06258824 Completed - Pancreatic Cancer Clinical Trials

MicroRNAs as Bile-based Biomarkers in Pancreaticobiliary Cancers

MIRABILE
Start date: January 1, 2018
Phase:
Study type: Observational

pancreatic or biliary-tract cancer can be a serious diagnosis, as many patients present too late for surgery. Cancer cells have been found to release small messenger molecules called that regulate cancer genes called microRNAs (miRNAs). The goal of this observational study is to learn about the role of miRNAs from bile and blood samples in patients with pancreatic cancer and bile duct cancer. The main question[s] it aims to answer are: - Can this detect patients presenting with jaundice (yellow-skin) undergoing endoscopy? - Can this distinguish between the types of cancer? Participants will have blood and bile samples collected prior to diagnosis and their clinical pathway will be followed up for 6 months.

NCT ID: NCT06256055 Recruiting - Colorectal Cancer Clinical Trials

Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors

Start date: March 5, 2024
Phase: Phase 1
Study type: Interventional

This is a first-in-human, single-arm, open-label, dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics, immunogenicity and preliminary efficacy of UCMYM802 (Circular mRNA encoding Anti-Mesothelin CAR-T) injection in patients with Mesothelin-positive advanced malignant solid tumors.